相关实验视频

Updated: Jan 12, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

验证CCL20驱动的CAR-γδ T分泌PD-1封锁,增加了对固体瘤的贩运

Dengji Zhang^1,2, Yuan Tang¹, Wei Sun²

¹State Key Laboratory of Genetic Engineering and Engineering Research Center of Gene Technology, Ministry of Education, Institute of Genetics, School of Life Sciences, Yiwu Research Institute, Fudan University, Shanghai, China.

|October 31, 2025

概括

工程化CAR-T细胞 (CAR-E276) 通过改善瘤透和克服免疫抑制,对固体瘤显示出有前途. 这种CAR-T疗法实现了显著的瘤减少,而不会导致移植对宿主疾病 (GvHD).

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
细胞疗法细胞疗法

背景情况:

在固体瘤治疗中,CAR-T细胞疗法面临着挑战,包括瘤透不良和免疫抑制瘤微环境.
克服这些障碍需要有效的细胞输送和免疫逃避策略.
结合化学激素引导和免疫抑制阻断提供了一个潜在的解决方案.

研究的目的:

开发和验证用于固体瘤的增强型CAR-T细胞疗法.
在非小细胞肺癌模型中评估新型CAR-T结构 (CAR-E276) 的疗效和安全性.

主要方法:

开发一种针对EGFR的CAR-γδ T细胞 (CAR-E276),共同表达CCR6并分泌PD1阻塞.
在体内验证使用非小细胞肺癌 (NSCLC) CDX模型.

主要成果:

卡尔-E276证明了高效的贩运瘤组织.
该疗法确保了长时间的CAR-T细胞持久性,并实现了强大的瘤杀伤效果.
没有观察到移植对宿主疾病 (GvHD).

结论:

整合化基因,检查点阻塞和γδ T 细胞特性,可增强固体瘤中CAR-T 细胞的功能.
卡尔-E276显示出用于现货和异种应用的潜力.
这些发现为开发用于固体瘤的先进CAR-T疗法提供了洞察力.

关键词:

癌症癌症癌症癌症细胞疗法是一种细胞疗法.免疫反应的免疫反应.

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.